Rigel Pharmaceuticals (RIGL) news
Recent news
Rigel Pharmaceuticals, Inc.: H.C. Wainwright raises target price to $85 from $57
On August 5, 2026, H.C. Wainwright revised its price target for Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL), raising it from $57 to $85, while maintaining its "Buy" rating . This update follows Rigel’s strong quarterly performance, where the biotechnology firm reported earnings of $0.88 per…
AInvest Wire · Aug 14, 2026Rigel Pharma 2Q total revenue $78.7M, est. $69.1M
AInvest Wire · Aug 4, 2026Rigel Pharma 2Q R&D expenses $14.0M, est. $12.7M
AInvest Wire · Aug 4, 2026Rigel Pharmaceuticals Inc: Jefferies raises target price to $55 from $50
Jefferies has revised its price target for Rigel Pharmaceuticals Inc (RIGL), raising it to $55 from $50, reflecting a positive reassessment of the company’s outlook [1]. The adjustment follows an analysis of Rigel’s recent developments, including progress in its drug development pipeline and market…
AInvest Wire · Jul 27, 2026Rigel Pharmaceuticals - appoints Alison L. Hannah as executive vice president and chief medical officer effective July 1, 2026 - SEC filing
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced the appointment of Alison L. Hannah, M.D., as Executive Vice President and Chief Medical Officer, effective July 1, 2026 . Dr. Hannah, who had served on Rigel’s Board since May 2021, resigned from the board to assume the new role. She succeeds…
AInvest Wire · Jul 1, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.